GeNeuro: failure of phase 2 study in Covid long

(CercleFinance.com) - GeNeuro remained unchanged on Friday morning on the Paris Bourse, where sell orders were pouring into the market following the failure of its Phase 2 study in post-Covid-19 syndrome.


Initial results from the trial show that treated patients had no clinically significant improvement over placebo on the primary endpoint measuring improvement in fatigue.

The majority of secondary endpoints also showed no material effect.

The trial - which involved over 200 patients in Switzerland, Spain and Italy suffering from post-Covid-19 neuropsychiatric syndromes - was designed to test the efficacy of temelimab versus placebo.

Following these disappointing results, the company decided to further reduce operating costs and headcount in order to preserve cash, terminating the employment contracts of seven out of nine employees of the parent company, including those of members of the management team.

All employees and managers will work during their notice period, of up to six months, to implement a new strategic plan.

The company says it will continue to look for ways to advance or monetize its multiple sclerosis and amyotrophic lateral sclerosis development assets, as well as its human endogenous retrovirus (HERV) platform.

Copyright (c) 2024 CercleFinance.com. All rights reserved.